Milestone Pharmaceuticals (MIST) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Milestone Pharmaceuticals (MIST) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 64.4% versus a loss of 75.3%. Neumora Therapeutics is the larger company by market cap ($90.2 million vs $88.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | NMRA |
|---|---|---|
| Share price | $0.7121 | $0.4798 |
| Market cap | $88.66M | $90.15M |
| 1-day change | -5.96% | +2.46% |
| YTD return | -64.75% | -73.20% |
| 1-year return | -64.39% | -75.27% |
| 5-year return | -87.93% | — |
| EPS (TTM) | $-0.68 | $-1.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.06 | $3.65 |
| 52-week low | $0.709 | $0.45 |
| Distance from 52-week high | -76.73% | -86.85% |
| Analyst consensus | none | none |
| Avg. price target upside | +722.92% | +1179.70% |
| Average volume | 1.40M | 1.19M |
| Shares outstanding | 124.50M | 187.90M |
| Employees | 38 | 63 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MIST has outperformed NMRA by 10.9 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Healthcare · Biotechnology · 38 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Healthcare · Biotechnology · 63 employees
MIST vs NMRA FAQ
Which is bigger, Milestone Pharmaceuticals or Neumora Therapeutics?
Neumora Therapeutics (NMRA) is larger, with a market capitalization of $90.15M compared with $88.66M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or NMRA?
MIST returned -64.39% over the past 12 months, compared with -75.27% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.